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ABSTRACT  
Introduction 
Chronic pain is often managed using co-prescription of analgesics and adjuvants, with 
concomitant medication prescribed for co-morbidities. Patients may have suboptimal 
response to some analgesics or be at risk of drug interactions or adverse drug reactions due 
to polypharmacy affecting CYP2D6 enzyme activity. The aim of the service improvement 
project was to determine the proportion of patients referred to a specialist pain service in the 
U.K. National Health Service (NHS) by GPs who were at risk of suboptimal analgesic 
response or adverse drug reactions due to CYP2D6 inhibition through polypharmacy. This 
was achieved by reviewing clinical prescribing information provided by GPs at time of 
referral.  
  
Methods 
A review of information provided in GP letters from 250 patients referred to a NHS hospital 
pain service over a 3 month period. Information about current and concomitant medications 
was analysed to identify the potential for CYP2D6 inhibition and adverse events.      
 
Results 
Letters failed to provide information about current pain medication for 20 (8%) patients. 
There was no information about non-pain concomitant medication for 54 (23.5%) of the 230 
patients with information about current pain medication. Fifty two (29.5%) of 176 patients 
with information about non-pain concomitant medication were prescribed at least one 
CYP2D6 inhibitor. Thirty five (19.9%) patients were identified as being at risk of an adverse 
drug reaction and 33 (18.75%) patients at risk of suboptimal analgesic response due to co-
administration of CYP2D6 inhibitors.   
 
Conclusion 
The review revealed the need for improved detail in GP referral letters used to transfer care 
to UK National Health Service hospital pain clinics. There is a need to consider of an 
individual’s CYP2D6 phenotype when prescribing analgesic prodrugs to manage persistent 
pain. Caution is needed when patients are co-prescribed codeine or tramadol with selective 
serotonin reuptake inhibitors.   
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INTRODUCTION 
Chronic pain is a complex condition affecting 1 in 5 adults with increasing prevalence 
through the lifespan1,2,3. Co-morbidities include diabetes, hypertension and cardiovascular 
disease4. Management is difficult and patients are often prescribed a variety of analgesics 
and drugs not typically prescribed as analgesics but are beneficial in pain management (i.e. 
pain adjuvants such as tricyclic antidepressants)4,5,6. A trial and error approach is often used 
when prescribing. Inadequate pain relief can lead to sequelae such as depression, poor 
mobility and insomnia which may result in referral to a specialist secondary care pain 
service4,7,8.  
 
Achieving a pain treatment plan during General Practitioner (GP) consultations is 
challenging because of time constraints9. General practitioners need to assess how 
individuals respond to drugs. Polymorphic variations of genes affect the fate of many drugs 
and this needs to be considered to optimise therapeutic drug response. Cytochrome P450 
enzymes are responsible for the biotransformation of many drugs and cause variability in 
drug pharmacokinetics and response. There are 17 cytochrome P450 families in man that 
are encoded by 57 functional genes. Six cytochrome P450 enzymes have important roles in 
drug metabolism CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP2E1, and CYP3A4. It is 
estimated that the metabolism of 25-30% of prescribed drugs requires CYP2D6. The 
CYP2D6 gene has polymorphic variability with over 100 known allelic variants resulting in 
four CYP2D6 phenotypic groups: poor metaboliser (PM) with no CYP2D6 activity; 
intermediate metaboliser (IM) with reduced activity; extensive metaboliser (EM) with normal 
activity; and ultra-rapid metaboliser (UM) with greater than normal activity10. 
 
The CYP2D6 enzyme is involved in the metabolism of analgesic prodrugs such as codeine 
and tramadol that are reliant on the activity of CYP2D6 for conversion to the active form.  
Individuals who are PM, IM and UM phenotypes may experience suboptimal analgesic 
response due to low plasma concentrations of active metabolites. They may also experience 
adverse drug reactions (ADRs) to higher than expected plasma concentrations of the 
unmetabolised drug. Combining analgesic prodrugs reliant on CYP2D6 with pain adjuvants 
or non-pain concomitant medication that also induce CYP2D6 activity may cause toxicity due 
to elevated levels of the active form of the prodrug. Inhibition of CYP2D6 through co-
prescribed pain adjuvants and non-pain medication can reduce CYP2D6 activity by 50-
100%22. A strong CYP2D6 inhibitor would change an EM phenotype to a PM phenotype and 
a moderate/weak CYP2D6 inhibitor would change an EM to an IM/EM phenotype. In both 
cases, suboptimal analgesic response and ADRs could occur if the individual was co-
prescribed codeine or tramadol for persistent pain. 
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A six year study of 65,526 hospitalised patients found that one in five patients were co-
prescribed a CYP2D6 inhibitor with the potential to prevent prodrug activation11. The aim of 
the service improvement project was to determine the proportion of patients referred to a 
specialist pain service in the U.K. National Health Service (NHS) by GPs who may be at risk 
of suboptimal analgesic response or adverse drug reactions due to CYP2D6 inhibition 
through polypharmacy. This was achieved by reviewing clinical prescribing information 
provided by GPs at time of referral. It was hoped that the findings could be used to aid 
clinical and prescribing decisions without conducting CYP2D6 genotyping or phenotyping.  
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METHODS 
A service improvement project was undertaken at the pain service of a large NHS teaching 
hospital at a major city in the UK (Leeds).  A protocol was designed by the authors and peer 
reviewed by members of the pain service team which resulted in only minor typographical 
changes. The protocol was reviewed by the Leeds Teaching Hospitals NHS Trust Research 
and Innovation Research Governance Manager who confirmed it was not research and 
requested it to be recorded on the NHS Trust’s Clinical Audit Database. The project involved 
reviewing GP referral letters for specialist pain management that were received by the pain 
service from 1 January 2013 to 31 March 2013. Referrals from other sources such as NHS 
consultants were excluded.  
 
A data extraction sheet was devised and piloted using ten GP referral letters with only minor 
amendments made to the design. The final data extraction sheet documented current 
pharmacological treatment prescribed by the GP at the time of referral and previous 
pharmacological treatment for the current episode of pain including analgesics, pain 
adjuvants and non-pain concomitant medication. Data extraction was performed by the 
principal investigator (HR), two pain research nurses and a clinical trial administrator. Data 
was transferred to a dedicated database by the clinical trials administrator and crossed 
checked for accuracy by a research nurse.  
 
The characteristics of clinical prescribing information provided by the GP were assessed for 
completeness including current and recent analgesic prescription, pain adjuvants, and non-
pain concomitant medications. Information about non-drug pain management was not 
extracted. Drugs prescribed for each patient were categorised according to their 
pharmaceutical class as defined by the British National Formulary (BNF)12 and the British 
Pain Society Opioid Guidelines13. Analgesic drugs reliant on CYP2D6 activity to obtain 
analgesic efficacy were identified using prescribing guidelines for CYP2D6 phenotypes 
produced by Clinical Pharmacogenetics Implementation Consortium14,15  and the Dutch 
Pharmacogenetics Working Group14,16. Analgesic drugs that were identified were codeine 
(including codeine combinations such as co-codamol), tramadol and oxycodone, although 
there is an ongoing debate whether CYP2D6 phenotype for oxycodone affects analgesia or 
toxicity17.  
 
Descriptive statistics were used to analyse the type and number of analgesics and pain 
adjuvants across the patient data set. The completeness of prescribing information was 
presented as ‘missing information’ from the referral letter. Prescribed analgesics, pain 
adjuvants, and non-pain concomitant medications were categorised according to a list of 
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CYP2D6 inhibitors and their strength of inhibition (i.e. strong, moderate and weak) compiled 
by the investigating team from information provided by the US Food and Drug Administration 
(FDA)18 and the UK Medicines and Healthcare Products Regulatory Agency (MHRA)19 
(Table 1). Drugs were categorised as weak inhibitors if they were named in the literature by 
Flockhart20 and Baxter21 as CYP2D6 inhibitors but the extent of inhibition had not been 
confirmed by the FDA or the MHRA (Table 1). There were no inducers categorised by the 
FDA or MHRA, although Flockhart20 identified two inducers (rifampin and dexamethasone). 
The potential for drug interactions between analgesic prodrugs reliant on CYP2D6 and pain 
adjuvants or non-analgesic concomitant medications that inhibit or induce CYP2D6 activity 
was inferred by matching the prescription of each patient against the list of inhibitors and 
inducers.  
 
[Insert Table 1 here] 
 
There was no information about the patients CYP2D6 genotype or phenotype. Therefore it 
was not possible to infer the extent of suboptimal analgesic response or ADRs from GP 
prescribing of analgesic prodrugs reliant on CYP2D6, or from pain adjuvants or non-pain 
concomitant medications that inhibit or induce CYP2D6 activity either alone or in 
combination. Nevertheless, the magnitude of reduction of CYP2D6 activity for each inhibitor 
could be estimated using the CYP2D6 inhibition formulary by Borges et al.22. Thus, strong 
inhibitors were classified as having 100% reduction of CYP2D6 activity and moderate or 
weak inhibitors classified as having 50% reduction of CYP2D6 activity. This information was 
used to explore the magnitude of potential drug interactions. Clinical implications of drug 
interactions were assembled using prescribing guidelines for CYP2D6 phenotypes produced 
by Clinical Pharmacogenetics Implementation Consortium14,15 and the Dutch 
Pharmacogenetics Working Group14,16.  
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RESULTS 
There were 260 referrals over the three month period (Figure 1). Ten referrals were not from 
the patient’s GP and were excluded from the analysis. Referral letters of 20 of the 250 
patients (8%) did not include information about current pain medication and could not be 
used in subsequent analyses. Information about current pain medication was available for 
230 patients (127 females (55.2%) and 103 males (44.8%)). There was no information about 
analgesics and pain adjuvants that had been tried previously for 111 (48.3%) of the 230 
patients and no information about non-pain concomitant medication for 54 (23.5%) of 
patients.  
 
[Insert Figure 1 here] 
 
Analysis of prescribed analgesics and adjuvants  
Current medication consisted of 532 GP prescriptions of 40 different analgesic or pain 
adjuvant drugs (Table 2). The most frequently prescribed class of drugs was non-opioid 
analgesics (i.e. paracetamol and NSAID = 150/532 (28.2%) prescriptions for 150/230 
(65.2%) patients) followed by strong opioids (134/532 (25.1%) prescriptions for 134/230 
(58.3%) patients) and weak opioids (86/532 (16.1%) prescriptions for 86/230 (37.4%) 
patients). The most common analgesic drug prescribed was paracetamol (81/532 (15.2%) 
prescriptions for 81/230 (35.2%) patients) followed by tramadol (58/532 (10.9%) 
prescriptions for 58/230 (25.2%) patients) and co-codamol (56/532 (10.5%) prescriptions for 
56/230 (24.3%) patients). Pain adjuvant drugs were readily prescribed with similar numbers 
of prescriptions for tricyclic antidepressants (64/532 (12.0%) prescriptions for 64/230 
(27.8%) patients) and anticonvulsants (78/532 (14.6%) prescriptions for 78/230 (33.9%) 
patients). The most frequently prescribed tricyclic antidepressant (TCA) was amitriptyline 
(59/532 (11%) prescriptions for 59/230 (25.65%) patients) and the most frequently 
prescribed anticonvulsant was gabapentin (39/532 (7.3%) prescriptions for 39/230 (17.0%) 
patients) and pregabalin (38/532 (7.1%) prescriptions for 38/230 (16.5%) patients). 
 
[Insert Table 2 here] 
 
One hundred and thirty five referrals (58.7%) were prescribed at least one analgesic that 
was reliant on CYP2D6 to obtain analgesic efficacy. Only 22 (9.6%) patients were prescribed 
a single analgesic drug without any other medication (i.e. on its own without a pain adjuvant 
or a non-pain concomitant drug). Of these patients, 10 were prescribed a strong opioid, one 
a weak opioid, three a non-opioid and eight a pain adjuvant. Three patients were prescribed 
an analgesic drug reliant on CYP2D6 without a non-pain concomitant drug and the analgesic 
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efficacy for these three patients would be solely dependent on their CYP2D6 phenotype 
(which was not known).  
 
Two hundred and eight (90.4%) patients were prescribed more than one drug (i.e. any 
combination of analgesic, pain adjuvant and non-pain medication). The most common 
prescription was two drugs from a combination of analgesic and/or pain adjuvant (80 
(34.8%) patients). Two patients (0.9%) had been prescribed seven analgesic and/or 
adjuvant drugs (Table 3). One hundred and sixty seven (72.6%) patients were prescribed 
more than one pain medication (i.e. any combination of analgesic and/or pain adjuvant). 
 
[Insert Table 3 here] 
 
Analysis of potential CYP2D6 inhibition by polypharmacy  
Information about non-pain concomitant medication was available for 176 patients and was 
used in the subsequent analyses. No patients were prescribed a CYP2D6 inducer (i.e. 
rifampin or dexamethasone). Fifty two (29.5%) of these 176 patients were prescribed at least 
one known CYP2D6 inhibitor (Figure 2). Nine (5.1%) of the 176 patients were prescribed a 
strong inhibitor that would produce complete inhibition of CYP2D6 and 43 (24.4%) were 
prescribed an inhibitor that would reduce CYP2D6 activity by 50% (moderate inhibitor n = 8, 
weak inhibitor n = 35).  Four (2.3%) patients were prescribed two or more inhibitors 
concurrently (i.e. strong + weak; moderate + weak; weak + weak; weak + weak + weak + 
weak). Seven (4.0%) patients were prescribed at least one analgesic that was reliant on 
CYP2D6 in combination with at least one pain adjuvant that had the potential to inhibit 
CYP2D6 activity. Two (1.1%) patients were prescribed tramadol and codeine (both reliant on 
CYP2D6 activity) with duloxetine which is a pain adjuvant known to inhibit CYP2D6. Twenty 
six (14.8%) patients were prescribed at least one analgesic that was reliant on CYP2D6 in 
combination with at least one non-pain concomitant drug that had the potential to inhibit 
CYP2D6. There were no patients that were prescribed an analgesic drug reliant on CYP2D6 
combined with both pain adjuvants and non-pain concomitant drugs with the potential to 
inhibit CYP2D6. 
 
[Insert Figure 2 here] 
 
Thirty five (19.9%) of the 176 patients were at risk of clinically significant drug interactions 
(Figure 3) and 33 patients (18.75%) were at risk of suboptimal analgesic response due to co-
administration of CYP2D6 inhibitors. At risk patients may have included an unknown number 
of UMs where suboptimal response would not occur if co-prescribed a moderate/weak 
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CYP2D6 inhibitor. Two patients (1.1%) were at risk of toxicity from high levels of aripiprazole 
(antipsychotic) and clomipramine (TCA) due to a lack of elimination by CYP2D6 inhibition23. 
Published prescribing guidelines for aripiprazole and clomipramine recommend reducing the 
standard dose by up to 67% in PMs to prevent ADRs14,15. Seventeen (9.7%) patients were at 
risk of moderate to weak CYP2D6 inhibition from non-selective serotonin reuptake inhibitors 
such as duloxetine (pain adjuvant), diltiazem (antihypertensive) and oral contraceptives that 
cause up to a 50% reduction in CYP2D6 activity. Four patients (2.3%) were at risk of ADRs 
from higher than expected plasma concentrations of amitriptyline which is eliminated via 
metabolism catalysed by CYP2D6. One patient was at risk of breast cancer relapse due to 
CYP2D6 inhibition and lack of biotransformation of tamoxifen, an anti-oestrogen 
prodrug14,16,19,22. Sixteen patients (9.1%) were at risk of drug interactions due to co-
prescription of a selective serotonin reuptake inhibitor (SSRI). Seven (4%) patients were 
prescribed fluoxetine or paroxetine which are strong CYP2D6 inhibitors producing complete 
inhibition of CYP2D6 activity. A further seven patients (4%) were prescribed sertraline or 
citalopram which are moderate/weak CYP2D6 inhibitors producing 50% reduction of 
CYP2D6 activity. Examples of prescribing resulting in limited analgesic efficacy and/or risk of 
ADRs included: 
 co-codamol + strong CYP2D6 inhibitor with no other analgesia prescribed (n=1): no pain 
relief  
 tramadol + moderate or weak CYP2D6 inhibitor with no other analgesia prescribed 
(n=3): at risk of limited pain relief 
 co-codamol + tramadol + moderate or weak CYP2D6 inhibitor  with no other analgesia 
prescribed (n=1): at risk of limited pain relief  
 co-codamol + strong SSRI CYP2D6 inhibitor + other analgesics (n=4): at risk of limited 
pain relief  
 tramadol + strong or moderate SSRI CYP2D6 inhibitor (n=11): at risk of serotonin 
syndrome  
Some patients were prescribed nortriptyline but none of them were co-prescribed CYP2D6 
inhibitors.  
 
[Insert Figure 3 here] 
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DISCUSSION 
Statement of principal findings 
This review of 230 referrals by GPs to a NHS hospital pain clinic over the three month period 
found that 40 different analgesics or pain adjuvants were prescribed reflecting a population 
of patients refractive to treatment and requiring specialist pain management. Referral letters 
contained no information about current pain medication for 8% of patients. No information 
about non-pain concomitant medication was provided for 23.5% of patients where current 
pain medication was known. 58.7% of patients had been prescribed at least one analgesic 
that was reliant on CYP2D6 to obtain analgesic efficacy. Over 90% of these patients had 
been prescribed more than one drug. Co-administration of at least one CYP2D6 inhibitor 
was identified in 29.5% of 176 patients with referral letters that contained relevant 
information. There was a risk of a drug interaction resulting in an adverse drug reaction for 
19.9% of these patients and a suboptimal analgesic response for 18.75% of patients.  
 
Meaning of the study and implications for clinicians 
Prescriptions for codeine, co-codamol and tramadol have risen over the last decade yet 
CYP2D6 phenotype of patients is not available to most GPs at the point of prescribing.. Up 
to 25% of the Caucasian population may be PMs, IMs or Ums with no or reduced CYP2D6 
activity and at risk of suboptimal analgesic response and/or ADRs from toxicity24,25. 
Polypharmacy confounds the problem and our finding that over half of patients had been 
prescribed at least one analgesic reliant on CYP2D6 is of concern. We estimated that there 
was a risk of clinically significant drug interactions for 19.9% of patients in our sample and a 
risk of suboptimal analgesia for 18.7% of patients.  
 
The risk of ADRs resulting from co-prescription of SSRIs, predominantly sertraline, 
citalopram and fluoxetine, was of particular concern with 6.25% of patients at risk of 
serotonin syndrome. GPs need to be aware that the risk of serotonin syndrome increases 
with the co-prescription of SSRIs with tramadol and fentanyl. There was also risk of toxicity 
from amitriptyline, aripiprazole and clomipramine, and a risk of suboptimal response to the 
tamoxifen. There remains an ongoing debate as to whether CYP2D6 activity is crucial to 
tamoxifen metabolism and breast cancer relapse19,26,27. When cases of CYP2D6 inhibition 
through polypharmacy or genetic polymorphisms present at clinic drug doses should be 
lowered in line with prescribing guidelines to reduce the potential for ADRs14,15,16 . The risk of 
drug interactions and ADRs from CYP2D6 induction is generally low as dexamethasone and 
rifampin are the only drugs with potential for induction20,28. Neither had been prescribed in 
our sample population. 
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The review demonstrates that GPs should be diligent when co-prescribing drugs dependent 
on CYP2D6 activity. It also revealed the need for improved detail in referral letters in line 
with new national standards when care is transferred across the ‘care boundaries’ of primary 
to secondary care29,30,31. Poor communication of medication history and prescribing not 
carefully thought through is costly to patient well-being and the NHS11,32,33,34,35,36.   
 
Implementation of improvements to service 
GP referrals that were identified at risk of suboptimal analgesic response and/or ADRs 
through inhibition of CYP2D6 from polypharmacy were notified to the consultant pain 
specialist for review. The pain consultant conveyed the findings of the initial clinical 
assessment in the pain clinic to the GP with an appropriate treatment plan (e.g. change 
analgesic, change in non-pain concomitant medication, or other clinically relevant action). 
The patient was followed up in the pain clinic as per standard care. In addition, the service 
has been improved so that the consultant pain specialist reviewing the patient undertakes a 
medication review for CYP2D6 inhibition at the clinic visit to identify individuals who are at 
risk of their phenotype changing because they are prescribed a CYP2D6 substrate in 
combination with a CYP2D6 inhibitory drug (i.e. phenocopying). For example, an EM may 
appear to be an IM or a PM due to CYP2D6 inhibition by the confounding drug. The use of 
online tools such as SuperCYP (http://bioinformatics.charite.de/supercyp/) can aid 
identification of inhibition of CYP enzymes from polypharmacy. Our findings suggest that 
GPs prescribing codeine and tramadol may lack knowledge about the impact of CYP2D6 
polymorphisms on patient care, suggesting a need for continuing professional development 
on CYP2D6 and pain pharmacology. 
 
Limitations of the project  
It was necessary to exclude 23.5% patients from the analysis of CYP2D6 inhibition as no 
information was provided on co-prescribed medication. The review was limited to clinical 
prescribing information provided by the GP at the time of referral and did not gather 
information about prescribing rationale, including drug titration. Referral letters did not 
contain specific information about supplementary ‘over the counter’ medication, dietary 
intake and herbal supplements that had the potential to inhibit CYP2D6. It is important that 
prescribers undertake a complete medication review so that patients disclose this 
information and it is disclosed in referral letters.  
 
Future research 
Prescribers may engage more fully with CYP2D6 prescribing guidelines if CYP2D6 
screening could be conducted in a reliable, easily executed and cost effective manner. As 
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CYP2D6 genotyping is not readily available in the NHS the ability to infer an individual’s 
phenotype at the point of care would be a valuable tool for healthcare professionals. There is 
a need to develop a cost effective method of inferring phenotype that is easily utilised in a 
clinical setting and therefore we have undertaken a follow-up study investigating the 
prevalence, genetic profile and phenotype frequencies of participants with persistent pain 
who do not respond to oral codeine. 
 
In conclusion, prescribers need to be aware of the potential impact of polymorphic variability 
of the CYP2D6 gene on the analgesic response to common analgesics such as codeine and 
tramadol. To reduce the incidence of serious drug interactions and ADRs such as serotonin 
syndrome, prescribers also need to be aware of the risk CYP2D6 inhibition from 
polypharmacy, especially when patients are co-prescribed tramadol. It is critical that GP 
referral letters contain sufficient detail about current and past medication to guide pain 
practitioners in future decisions about treatment. 
 
Take home message: Referring a patient to a specialist pain service is a crucial point in 
their management. Many GP referral letters did not provide sufficient detail about current 
and past medication to aid specialist pain clinicians. This project demonstrated the potential 
impact of CYP2D6 inhibition in patients referred for specialist pain management. Analysis of 
prescribing information in referral letters found a potential suboptimal analgesia and adverse 
events due to polypharmacy causing inhibition of the CYP2D6 enzyme. Clinicians need to be 
more aware of the impact of CYP2D6 inhibition on response to analgesics.  
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FIGURE LEGENDS 
 
Figure 1 
Flow of data gathered from General Practitioner (GP) referral letters  
 
Figure 2 
Analysis of CYP2D6 inhibition from information provided in 176 GP referral letters. DIs = Drug 
Interactions; ADRs = Adverse Drug Reactions; SSRIs = Selective Serotonin Reuptake Inhibitors 
 
Figure 3 
Potential clinically significant adverse drug reactions due to CYP2D6 inhibition 
Key: ADRs = Adverse Drug Reactions; SSRIs = Selective Serotonin Reuptake Inhibitors; TCAs 
= Tricyclic Antidepressants 
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Table 1 
Drugs that are known to be CYP2D6 inhibitors that were used for identification of potential drug interactions in this review. The list was 
compiled using information from the following sources: FDA18, MHRA19, Flockhart20, Baxter21 
 
Strong CYP2D6 
inhibitors   
≥5-fold increase in area 
under the curve or 
>80% decrease in 
clearance 
Moderate CYP2D6  
inhibitors   
≥2 but <5-fold increase in 
area under the curve or 
50-80% decrease in 
clearance 
Weak CYP2D6 inhibitors   
≥1.25 but <2-fold increase in area under the 
curve or 20-50% decrease in clearance 
Known CYP2D6 inhibitors 
(classed as weak for the purpose of this audit) 
Bupropion18,19,20,21 
Fluoxetine18,19,20,21 
Paroxetine18,19,20,21 
Quinidine18,19,20,21 
Cinacalcet20 
 
Duloxetine18,20,21 
Cinacalcet18,19 
Terbinafine18,21 Sertraline20 
 
 
Amiodarone18,20,21 
Celecoxib18,20 
Cimetidine18,21 
Desvenlafaxine18 
Diltiazem18 
Diphenhydramine18,20,21               
Echinacea18 
Escitalopram18.20 
Febuxostat18  
Gefitinib18  
 
Hydralazine18 
Hydroxychloroquine18 
Imatinib18 
Methadone18,20 
Oral Contraceptives18 
Propafenone18,21  
Ranitidine18,20  
Ritonavir18,20,21  
Sertraline18,21  
Telithromycin18  
Verapamil18 
Chlorpheniramine20 
Clomipramine20 
Chlorpromazine20 
Citalopram20  
Clemastine20 
Clomipramine20  
Cocaine20 
Dextropropoxyphene21  
Doxepin20 
Doxorubicin20 
Halofantrine20 
Histamine H1 antagonist20  
Hydroxyzine20 
Levomepromazine20 
Metroclopramide20      
Mibefradil20  
Midodrine20  
Moclobemide20 
Perphenazine20  
Reduced haloperidol20  
SSRIs21 
Ticlopidine20  
Tripelen-namine20 
Valdecoxib21 
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Table 2 
Analgesics, pain adjuvants and concomitant medication identified from referral letters from General Practitioners with associated CYP2D6 
inhibitor strength and risk of drug interactions (DIs) and adverse drug reactions (ADRs)    
Drug Analgesic efficacy 
dependent on CYP2D6  
Strength of 
CYP2D6 
Inhibition  
 
Risk of DIs & ADRs due 
to  CYP2D6 inhibition 
Current medication 
(n=prescriptions) 
 
 
Opioid Analgesics 
    
 
a) Strong Opioids     134 
 Morphine  N/A  28  
 Transdermal 
buprenorphine (Butrans) 
 N/A  10  
 Transdermal 
buprenorphine  (Transtec) 
 N/A  13  
 Fentanyl  N/A  13  
 Tramadol Y N/A Y 58  
 Oxycodone Y N/A Y 12  
b) Weak Opioids     86  
 Co-codamol Y N/A Y 56  
 Codeine Y N/A Y 9  
 DF118  N/A  17  
 Co-dydramol  N/A  2  
 Co-proxamol  WeakB  2  
 
Non-opioid Analgesics 
    
 
a) Paracetamol    81  
b) Non-steroidal anti-inflammatory    69  
 Diclofenac  N/A  23  
 Ibuprofen  N/A  15  
 Naproxen  N/A  16  
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 Piroxicam  N/A  4  
 Meloxicam  N/A  4  
 Celecoxib  Weaka  3  
 Etoricoxib  N/A  2  
 Ketoprofen  N/A  2  
     
 
Pain Adjuvants 
    
 
a) TCA    64  
 Amitriptyline  N/A Y 59  
 Nortriptyline  N/A Y 3  
 Trazadone  N/A  2  
b) Anti-convulsants    78  
 Pregabalin  N/A  38  
 Gabapentin  N/A  39  
 Carbamazepine    1  
c) Other    20  
 Tizanidine (Muscle 
Relaxant) 
 N/A  1  
 Duloxetine  Moderatea  6  
 Ketamine  N/A  1  
 Baclofen  N/A  4  
 Lidocaine Patch  N/A  4  
 Capsaicin Cream  N/A  3  
 Methcarbamol  N/A  1  
     
Concomitant Medication      
 Fluoxetine  Stronga  6  
 Paroxetine  Stronga  3  
 Sertraline  Moderateb/Weaka  7  
 Citalopram  Weakb  9  
 Oral Contraceptives  Weaka  4  
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 Ranitidine  Weakb  5  
 Diltiazem  Weaka  6  
 Metoclopramide  Weakb  3  
 Terbinafine  Moderatea  2  
 Escitalopram  Moderatea  1  
 Hydroxychloroquine  Weaka  1  
 Clomipramine  Weakb  1  
 Tamoxifen  N/A  1  
 Aripiprazole  N/A Y 1  
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Table 3 
Number of prescriptions of analgesic and pain adjuvant drugs from the 230 referrals that had information about current pain medication. Unless 
otherwise stated, percentages represent number of prescriptions (numerator) compared with the total number of prescriptions per column 
(number of prescriptions for each patient (denominator)).  
 
 
Number of prescriptions per patient One Two Three Four Five Six Seven 
Number of patients (% of n=230) 63(27.4%) 79(34.3%) 54(23.5%) 27(11.7%) 3(1.3%) 2(0.9%) 2(0.9%) 
Number of prescriptions 63 158 162 108 15 12 14 
 
Number of opioid prescriptions  
a) Strong opioids 20(31.7%) 37(23.4%) 38(23.5%) 29(26.8%) 1(6.7%) 4(33.3%) 5(35.7%) 
b) Weak opioids 13(20.6%) 27(17.0%) 27(16.7%) 15(13.9%) 3(20.0%) 1(8.3%) 0(0%) 
 
Number of non-opioid prescriptions 
a) Paracetamol 4(6.3%) 25(15.8%) 26(16.0%) 21(19.4%) 1(6.7%) 2(16.7%) 2(14.3%) 
b) Non-steroidal anti-inflammatory  8(12.7%) 24(15.1%) 21(13.0%) 10(9.3%) 4(26.6%) 1(8.3%) 2(14.3%) 
 
Number of pain adjuvant prescriptions 
a) Tricyclic antidepressant 8(12.7%) 14(8.9%) 26(16.0%) 10(9.3%) 3(20.0%) 2(16.7%) 1(7.1%) 
b) Anticonvulsant 9(14.4%) 26(16.6%) 21(13.0%) 15(13.9%) 3(20.0%) 2(16.7%) 2(14.3%) 
c) Other 1(1.6%) 5(3.2%) 3(1.8%) 8(7.4%) 0(0%) 0(0%) 2(14.3%) 
 
 
 
 
